Resources from the same session
440O - First in human study of the mRNA-based cancer vaccine CVGBM in patients (pts) with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma (GBM): First results from the dose escalation phase
Presenter: Ghazaleh Tabatabai
Session: Proffered paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
441O - A phase I clinical trial on the intracranial administration of autologous CD1c(BDCA-1)+ /CD141(BDCA-3)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and nivolumab (NIVO) in patients with recurrent high-grade glioma (rHGG)
Presenter: Bart Neyns
Session: Proffered paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
442O - A phase I clinical trial of intrathecal injection of allogeneic CAR-γδT cells targeting B7H3 for the treatment of patients with recurrent glioblastoma
Presenter: Yulun Huang
Session: Proffered paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 440O, 441O and 442O
Presenter: Emeline Tabouret
Session: Proffered paper session: CNS tumours
Resources:
Slides
Webcast
Q&A
Session: Proffered paper session: CNS tumours
Resources:
Webcast
443O - A perioperative study of safusidenib in patients with IDH1 mutated glioma
Presenter: James Whittle
Session: Proffered paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
444O - The prognostic impact of CDKN2A/B heterozygous deletions in IDH-mutant glioma
Presenter: Franziska Ippen
Session: Proffered paper session: CNS tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 443O and 444O
Presenter: Monika Hegi
Session: Proffered paper session: CNS tumours
Resources:
Slides
Webcast